The effect of spinal cord-injury level on the outcome of XXXX treatment using @entity9381 .

@entity1 @entity322 @entity1494 @entity9381 @entity764 @entity2182 @entity130
AIM: The aim was to report the effectiveness and safety @entity9381 (Botox, Allergan, Inc., Irvine, CA, USA) intradetrusor injections in spinal cord-injured (SCI) @entity1 with refractory neurogenic detrusor overactivity. And to assess the result based on SCI level. MATERIALS AND METHODS: We reviewed the chart of 103 @entity1 with @entity1494 secondary to SCI at the rehab center who received @entity9381 in our Neurourology Department for treatment of lower urinary tract symptoms between January 2007 and December 2013. All @entity1 had a clinical examination, urinalysis, and an urodynamic study at baseline and 3 months after treatment as well as a visual analogue scale (VAS; range scale: 0-10) and a bladder diary checked for 3 days. 300 IU of @entity9381 , detrusor muscle injections were performed in 30 sites under cystoscopic guidance. Outcome measures included frequency of urge urinary @entity322 collected by bladder diaries; changes in urodynamic parameters such as maximum cystometric bladder capacity, reflex volume, maximum detrusor pressure; side-effects; antimuscarinic drug consumption and quality of life (QOL) measured with VAS. RESULTS: The study includes 32 female and 71 male with a mean @entity1 age of 29 years (range: 18-56 year). The effect of Botox injection on bladder function was observed within 1-2 week after treatment. The urodynamic parameters were improved significantly after treatment compared with baseline values. There were significant reductions in the frequencies of @entity322 episodes after treatment as seen in the voiding diary. A significant improvement in @entity1 satisfaction was found after treatment which was expressed on the VAS assessment, with an improvement of the mean of 3 points. @entity1 with @entity764 have better result compare to @entity130 @entity1 . The earliest recurrence of clinical symptoms was at 10 weeks. Overall, the mean duration of symptomatic improvement was 8 (2.5-21) months. CONCLUSION: Intradetrusor @entity9381 injections are an effective and well-tolerated treatment for @entity2182 that will increase @entity1 satisfaction and improve QOL with persisted clinical efficacy for more than 8 months.
